What Aurinia Pharmaceuticals Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 11 |
| Sells | 2 | 2 |
| Total trades | 2 | 41 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 2,791,049 |
| Disposed | 32,914 | 713,613 |
| Net activity | −32,914 | +2,077,436 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Robertson Stephen P. | Chief Legal Officer | Sep 10 | Sale for tax withholding · S | −11,939 | $15.95 | −$190K | 588,848 |
| Robertson Stephen P. | Chief Legal Officer | Aug 21 | Sale for tax withholding · S | −20,975 | $16.97 | −$356K | 600,787 |
| Tang Kevin | Chief Executive Officer | Jun 02 | Open-market buy · P | +206,005 | $15.28 | +$3.15M | 13,044,106 |
| Tang Kevin | Chief Executive Officer | Jun 01 | Open-market buy · P | +99 | $15.34 | +$1.52K | 12,838,101 |
| Tang Kevin | Chief Executive Officer | Jun 01 | Open-market buy · P | +343,521 | $15.28 | +$5.25M | 12,838,002 |
| Tang Kevin | Chief Executive Officer | May 29 | Open-market buy · P | +262,682 | $15.31 | +$4.02M | 12,494,481 |
| Tang Kevin | Chief Executive Officer | May 29 | Open-market buy · P | +2,299 | $15.35 | +$35.3K | 12,231,799 |
| Hearne Michael S | Chief Financial Officer | May 18 | Grant / award · A | +116,144 | — | — | 116,144 |
| Robertson Stephen P. | Chief Legal Officer | May 18 | Grant / award · A | +115,541 | — | — | 621,402 |
| Cole Ryan | Chief Operating Officer | May 18 | Grant / award · A | +116,144 | — | — | 116,144 |
| Keenan Greg | SVP, Chief Medical Officer | Mar 06 | Withheld — tax / exercise cost · F | −8,069 | $14.32 | −$116K | 154,449 |
| Tang Kevin | Director | Mar 03 | Open-market buy · P | +184,208 | $14.22 | +$2.62M | 12,229,500 |
| Tang Kevin | Director | Mar 02 | Open-market buy · P | +115,792 | $14.21 | +$1.65M | 12,045,292 |
| Tang Kevin | Director | Mar 02 | Open-market buy · P | +83,561 | $14.33 | +$1.2M | 11,929,500 |
| Miller Joseph M | Chief Financial Officer | Mar 02 | Withheld — tax / exercise cost · F | −37,511 | $14.21 | −$533K | 576,421 |
| Greenleaf Peter | Chief Executive Officer | Mar 02 | Withheld — tax / exercise cost · F | −100,890 | $14.21 | −$1.43M | 1,840,379 |
| Robertson Stephen P. | EVP, General Counsel | Mar 02 | Withheld — tax / exercise cost · F | −36,525 | $14.21 | −$519K | 505,861 |
| Donley Matthew Maxwell | Chief Operating Officer | Mar 02 | Withheld — tax / exercise cost · F | −40,761 | $14.21 | −$579K | 680,299 |
| Tang Kevin | Director | Feb 27 | Open-market buy · P | +1,600 | $14.38 | +$23K | 11,845,939 |
| Tang Kevin | Director | Feb 27 | Open-market buy · P | +214,839 | $14.12 | +$3.03M | 11,844,339 |
Loading...